ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
20 nov. 2023 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
03 nov. 2023 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab’s differentiated effects of targeting IL-13R vs IL-4RUsing an established...
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
27 oct. 2023 08h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established...
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
24 oct. 2023 08h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Discussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has...
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
18 oct. 2023 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveysRegister here to attend the webinar...
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
13 oct. 2023 09h30 HE
|
ASLAN PHARMACEUTICALS LIMITED
Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate eblasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a...
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
22 sept. 2023 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11 août 2023 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established...
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
06 juil. 2023 07h55 HE
|
ASLAN PHARMACEUTICALS LIMITED
Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks,...